Clinical assessment of disorders of the melatonin-forming function of the pineal gland and anemia in patients with chronic kidney disease stage 5 undergoing hemodialysis

Main Article Content

V.E. Kondratiuk
A.S. Petrova
O.V. Karpenko

Abstract

Background. The results of a number of studies have proved the relationship between the functional state of the pineal gland and renal function. However, violations of the melatonin-forming function (MFF) of the pineal gland in patients with chronic kidney disease (CKD) undergoing hemodialysis and its relationship with the development of anemia in this population is a poorly understood issue. The purpose: to conduct a clinical assessment of anemia in patients with stage 5 CKD who are treated with hemodialysis depending on clinical and demographic parameters, and to determine its correlation with the violation of MFF. Materials and methods. We examined 130 people (50 % of men) with stage 5 CKD undergoing hemodialysis treatment. Based on the level of melatonin in saliva, patients treated with hemodialysis were divided into two groups: group I — 110 individuals with impaired MFF, group II — 20 people with normal MFF. The control group included 20 healthy individuals matched for age and gender. All patients underwent clinical and laboratory studies: general and biochemical blood tests with determination of all indicators of blood iron metabolism, lipid profile, blood pressure measurement, body mass index calculation, evaluation of the salivary melatonin concentration at different periods of the day, as well as parathyroid hormone. Results. A significant prevalence of MFF disturbance was found in patients with stage 5 CKD, which are treated with hemodialysis, and its relationship with the development of anemia. Analysis of circadian melatonin levels depending on the severity of anemia demonstrated their profound impairment in patients with mode­rate severity of anemia, in which a significant difference was determined by the level of melatonin at night (p = 0.004). Correlation analysis showed a weak negative correlation between the level of hemoglobin and the duration of hemodialysis (r = –0.217; p < 0.05) that may indicate the progression of anemia with an increase in the duration of renal replacement treatment. Positive correlations were established between hemoglobin concentration and the level of daytime melatonin (r = 0.193; p < 0.05), and closer relationship — with the level of nighttime melatonin (r = 0.278; p < 0.05), which reflects the correlation between the violation of MFF and hemoglobin synthesis. A negative correlation was demonstrated between ferritin and hemoglobin level (r = –0.31; p < 0.05), as well as with serum iron concentration (r = –0.202; p < 0.05) and the level of transferrin (r = –0.234; p < 0.05). A negative correlation is determined between the level of ferritin and the daytime salivary melatonin (r = –0.202; p < 0.05), and the relationship of average strength — with salivary melatonin at night (r = –0.396; p < 0.05). When analyzing the level of transferrin, we determined the positive correlation of the latter with the daytime melatonin (r = –0.332; p < 0.05), and average correlation — with melatonin level at night (r = 0.447; p < 0.05). The inverse weak correlation was found between transferrin concentration and hemodialysis duration (r = –0.191; p < 0.05). Conclusions. A high frequency of MFF disturbance was demonstrated (84.6 %), which is associated with a significant prevalence of anemia and iron deficiency in patients with stage 5 CKD undergoing hemodialysis treatment. In people receiving renal replacement treatment, a relationship was established between the degree of pineal gland dysfunction and the severity of anemia; at that, it increases with an increase in the duration of hemodialysis treatment and the duration of hypertension. In hemodialysis patients, the concentration of ferritin reflects the activity of inflammation that increases with a violation of MFF. Pineal gland dysfunction and anemia have age-dependent nature: they are most severe in old age.

Article Details

How to Cite
Kondratiuk, V., A. Petrova, and O. Karpenko. “Clinical Assessment of Disorders of the Melatonin-Forming Function of the Pineal Gland and Anemia in Patients With Chronic Kidney Disease Stage 5 Undergoing Hemodialysis”. KIDNEYS, vol. 9, no. 1, Jan. 2020, pp. 20-28, doi:10.22141/2307-1257.9.1.2020.196913.
Section
Original Articles

References

Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(1):94–111. doi:10.1053/j.ajkd.2004.03.023.

United States Renal Data System (USRDS). USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and EndStage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD; 2013.

Kozljuk NI, Nikolajenko SS, Razvazhajeva OO; Institute of Nephrology NAMS of Ukraine, authors; Kolesnyk MO, editor. Nacional'nyj rejestr hvoryh na hronichnu hvorobu nyrok ta pacijentiv z gostrym poshkodzhennjam nyrok: 2017 rik [National Register of Chronic Patients kidney disease and patients with acute kidney damage 2017]. Kyiv; 2018. 183 p. (in Ukrainian).

Sica DA, Mannino R. Antihypertensive medications and anemia. J Clin Hypertens (Greenwich). 2007;9(9):723–727. doi:10.1111/j.1524-6175.2007.06296.x.

Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11(3):530–538.

Zaritsky J, Young B, Wang HJ, et al. Hepcidin – a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051–1056. doi:10.2215/CJN.05931108.

­Labonia W, Rubio D, Arias C. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology (Carlton). 2005;10(6):583–587. doi:10.1111/j.1440-1797.2005.00488.x.

Kondratiuk VE, Petrova AS, Karpenko ОV. Characterization of melatonin-forming function of pineal gland in patients with end-stage chronic kidney disease. Clinical endocrinology and endocrine surgery. 2019;(68):94–102. doi:10.30978/CEES-2019-4-94. (in Ukrainian).

Hrenak J, Paulis L, Repova K, et al. Melatonin and renal protection: novel perspectives from animal experiments and human studies (review). Curr Pharm Des. 2015;21(7):936–949. doi:10.2174/1381612820666140929092929.

Russcher M, Koch B, Nagtegaal E, van der Putten K, ter Wee P, Gaillard C. The role of melatonin treatment in chronic kidney disease. Front Biosci (Landmark Ed). 2012;17:2644–2656. doi:10.2741/4075.

Li DY, Smith DG, Hardeland R, et al. Melatonin receptor genes in vertebrates. Int J Mol Sci. 2013;14(6):11208–11223. doi:10.3390/ijms140611208.

Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2016;56:361–383. doi:10.1146/annurev-pharmtox-010814-124742.

Van der Putten K, Koch B, van Someren E, et al. The role of renal function loss on circadian misalignment of cytokines EPO, IGF-1, IL-6 and TNF-alfa in chronic renal disease. Neuro Endocrinol Lett. 2011;32(2):148–153.

Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant. 2013;28(7):1672–1679. doi:10.1093/ndt/gft021.

Likuvannja hvoryh na hronychnu hvorobu nyrok V HD stadii': adaptovana klinichna nastanova, zasnovana na dokazah, ta unifikovani klinichni protokoly [Treatment of patients with chronic kidney disease V HD stage: adapted evidence-based clinical setting and unified clinical protocols]. Kyiv: Poligraf-pljus; 2016. 228 p. (in Ukrainian).

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023. doi:10.1056/NEJMra041809.

Nabavi SM, Nabavi SF, Sureda A, et al. Anti-inflammatory effects of Melatonin: A mechanistic review. Crit Rev Food Sci Nutr. 2019;59(sup1):S4–S16. doi:10.1080/10408398.2018.1487927.

Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976–981. doi:10.1038/ki.2009.21.

Peng W, Lei M, Zhang J, Zhang Y. The protective effect of melatonin on the in vitro development of yak embryos against hydrogen peroxide-induced oxidative injury. Zygote. 2019;27(3):118-125. doi:10.1017/S0967199418000412.

Reiter RJ, Tan DX, Korkmaz A, Rosales-Corral SA. Melatonin and stable circadian rhythms optimize maternal, placental and fetal physiology. Hum Reprod Update. 2014;20(2):293–307. doi:10.1093/humupd/dmt054.